Skip to main content
. 2007 Feb 7;11(4):472–478. doi: 10.1007/s11605-006-0032-8

Table 5.

FDG-PET and CT in Patients who Received Chemotherapy With or Without Bevacizumab: Comparison With Pathological Results

  Bevacizumab − Bevacizumab + P value
PET
 TP 29 19
 True negative (complete response) 17 3
 FP 2 2
 FN 20 30
 Sensitivity 59% 39% 0.068
CT
 TP 33 31
 True negative (complete response) 13 5
 FP 6 0
 FN 16 18
 Sensitivity 67% 63% 0.9